Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 83 participants, all of whom received the study drug pirfenidone. Only 7 participants completed the study, while 76 did not complete it. The trial was primarily measuring how often participants experienced unwanted medical events (called adverse events) while taking the study drug. It also tracked several measures of lung function and breathing over time, as well as how long participants survived. The reported data shows that the vast majority of participants — 98.8% — experienced at least one adverse event (an unwanted medical occurrence linked to the study drug) during the trial. Of those, 59.0% experienced a serious adverse event (one serious enough to require hospitalisation or posing an immediate risk of dying, among other criteria), 36.1% had a severe adverse event (meaning it markedly limited their activity or required medical treatment), 21.7% experienced a life-threatening adverse event, 25.3% died, and 43.4% stopped taking the study drug because of an adverse event. For the lung function measures, the reported data shows that participants' lung capacity (measured as a percentage of what would be expected for a healthy person of the same age, sex and height) hovered around 65–70% across the various measurement points throughout the study. A separate measure of how well the lungs transfer oxygen into the blood sat at roughly 35–40% of the predicted healthy level across measurement points. Resting blood oxygen levels remained relatively stable across measurements, generally around 94–96%. The reported data also shows that the median survival time from the first dose was approximately 508.7 weeks (roughly 9–10 years), though the way this figure was calculated means it may reflect varying lengths of follow-up among participants. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 32026243) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Interstitial Lung Disease Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be able to understand and sign a consent form agreeing to take part in the study
- You must understand how important it is to follow the study rules, including restrictions on other medications, throughout the entire study
- You must be willing to travel to an approved regional center for all study-related appointments
- Some participants may be able to join through a special "roll-over" process if they were already enrolled through a previous related program (confirm with trial site)
- You must have symptoms consistent with a lung disease called IPF (idiopathic pulmonary fibrosis) that have lasted at least 3 months
- You must be between 40 and 85 years old
- At the time of first registering with a specific patient organization (NORD), your lung function tests must show your lungs are working at least 50% as well as expected for your age, and your ability to transfer oxygen into the blood must be at least 35% of what is expected
- At the time of joining the study itself, your lung function must be at least 45% of what is expected, and your oxygen transfer ability must be at least 30% of expected
- A special type of chest scan (a high-resolution CT scan) must clearly show signs of IPF
- If you are under 50 years old, you must have had a surgical lung biopsy confirming the specific pattern of lung scarring associated with IPF, with no signs pointing to a different diagnosis
- If you are 50 years old or older, at least one of several diagnostic tests (surgical lung biopsy, a small tissue sample taken through a breathing tube, or a fluid sample from the lungs) must support the IPF diagnosis, with no results suggesting a different condition
Who may not be able to join:
- There are no specific exclusion criteria listed in the provided information (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Percentage of Participants With a Treatment-Emergent Adverse Event (AE), Serious AE (SAE), Severe AE, Life-threatening AE, Death or Discontinuation Because of an AE
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.